| Document |
Document Title |
|
WO/2024/152536A1 |
An S-6-methyl nicotine salicylate and a preparation method therefor. The preparation method comprises: firstly, preparing an (S)-6-methyl nicotine salicylate seed crystal; then dissolving (S)-6-methyl nicotine in an organic solvent to fo...
|
|
WO/2024/147146A1 |
The present invention disclosed herein relates to a quaternary ammonium compound represented by Formula-I and simple, viable process for preparation thereof. Particularly, the present invention relates to novel therapeutically active qua...
|
|
WO/2024/141003A1 |
The present application discloses a hyaluronic acid derivative, which is specifically a hyaluronic acid ester, and is an ester synthesized from hyaluronic acid or salts thereof and salicylate. The hyaluronic acid ester disclosed by the p...
|
|
WO/2023/196900A9 |
Provided herein are solid forms comprising a compound of formula (I), or a stereoisomer, or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of synthesizing a compound of...
|
|
WO/2024/141534A1 |
The specification generally relates to crystalline forms of inhibitors of the NLRP3 inflammasome, pharmaceutical compositions comprising such crystalline forms, chemical processes useful for the preparation of inhibitors of the NLRP3 inf...
|
|
WO/2024/124354A1 |
In some example embodiments the invention relates to compositions comprising at least one N-acylethanolamine (NAE) and at least one of a cannabinoid, terpene, antioxidant or herbal extract. In other example embodiments the invention rela...
|
|
WO/2024/116780A1 |
The present invention provides: a resist composition that is improved in terms of a decrease in roughness and sensitivity, and that can suppress film reduction during development; a resist pattern formation method that uses the resist co...
|
|
WO/2024/117265A1 |
The present invention relates to binaphthyl compounds of the formula {I) that are suitable as monomers for preparing thermoplastic resins, such as polycarbonate resins, which have beneficial optical and mechanical properties and can be u...
|
|
WO/2024/106024A1 |
The present invention provides a temperature-responsive ionic liquid that improves the permeability of various drugs in the skin, mucous membranes, etc. The present invention provides a temperature-responsive ionic liquid comprising an a...
|
|
WO/2024/101044A1 |
Provided are a resist composition in which the temporal stability during storage is increased and a decrease in fine resolution after storage is reduced, a resist pattern formation method using said resist composition, and a compound use...
|
|
WO/2024/088287A1 |
A decarboxylation method for industrial hemp flowers and leaves. The method uses a vacuum microwave drying device to carry out the decarboxylation of hemp flowers and leaves, and comprises the steps of crushing hemp flowers and leaves, s...
|
|
WO/2024/090041A1 |
Provided are a radioactive-ray-sensitive resin composition and a pattern formation method that make it possible to form a resist film that has satisfactory storage stability, and also has excellent sensitivity and LWR performance when ne...
|
|
WO/2024/083839A1 |
The current invention relates to a Method for extracting phenolic aldehydes from a lignocellulosic biomass comprising the steps of: (i) mechanochemically reacting said lignocellulosic biomass with a dry base, thereby agglomerating said l...
|
|
WO/2024/075535A1 |
In the present invention, there is employed a resist composition having, as a base resin, a polymer compound that has constituent units derived from a compound expressed by general formula (a0−m). In the formula, W is a polymerizable-g...
|
|
WO/2024/059609A1 |
The present disclosure relates to pharmaceutical forms of a CD73 inhibitor, polymorphic forms of the pharmaceutical forms, pharmaceutical compositions comprising the pharmaceutical forms, and methods of treating subjects having cancer by...
|
|
WO/2024/055118A1 |
The present disclosure relates to a use of minor cannabinoids in the management or treatment of a seizure disorder in a patient. Minor cannabinoids include cannabichromene (CBC), cannabichromenic acid (CBCA), cannabigerol (CBG), cannabig...
|
|
WO/2024/056865A1 |
The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the ClC...
|
|
WO/2024/050641A1 |
There are provided compositions comprising at least one compound chosen from compound of formula (I), compound of formula (II), compound of formula (III) and compound of formula (IV): and a cannabinoid for use as a COX-2 inhibitor.
|
|
WO/2024/040182A1 |
Disclosed herein is the use of purified 2-S rimantadine or purified 2-R rimantadine or a pharmaceutically acceptable thereof to treat cancers and precancer lesions, including cancers and precancer lesions associated with papilloma virus ...
|
|
WO/2024/038835A1 |
A desulfurizing agent according to the present disclosure removes a sulfur compound from a sulfur compound-containing raw material. The desulfurizing agent is characterized by comprising a metal-organic structure, wherein: the metal-orga...
|
|
WO/2024/021625A1 |
A crystal form A of pramipexole xinafoate salt ((S)-(-)-2-amino-6-(propylamino)-4,5,6,7-tetrahydrobenzothia
zole bis(1-hydroxynaphthoate) and a preparation method for the crystal form A. The structural formula of the pramipexole xinafoat...
|
|
WO/2024/024818A1 |
[Problem] To provide a simpler method for producing a high-quality metal-organic structure. [Solution] The method for producing a metal-organic structure according to the present invention comprises: providing a stirrer equipped with a...
|
|
WO/2023/248241A1 |
Oral pharmaceutical composition of Cyclizine or pharmaceutically acceptable salt thereof The present invention relates to an oral liquid pharmaceutical composition comprising Cyclizine or pharmaceutically acceptable salt thereof and one ...
|
|
WO/2023/225144A1 |
The invention provides piperidinyl-methyl-purine amine salts, crystalline forms, pharmaceutical compositions, their use in inhibiting NSD2, and their use in the treatment of a disease or condition, such as cancer.
|
|
WO/2023/221793A1 |
The present invention provides use of a phenolic acid derivative in treating ischemic stroke. Specifically, the present invention provides use of a compound represented by the following formula (I), or a pharmaceutically acceptable salt ...
|
|
WO/2023/225403A2 |
This invention is directed to crystalline forms of cannabinoid acids, producing crystalline forms, and methods of use thereof.
|
|
WO/2023/207460A1 |
Disclosed are a cannabidiol derivative, a preparation method therefor and use thereof, particularly, use in the prevention and treatment of nervous system diseases (such as epilepsy and Parkinson's disease). The above cannabidiol derivat...
|
|
WO/2023/199907A1 |
The present invention employs a resist composition which generates an acid upon exposure to light and changes the solubility with respect to a developer solution by the action of the acid, and which contains a compound that is represente...
|
|
WO/2023/195222A1 |
The method for producing 3,5-di-tertiary-butylsalicylic acid according to one aspect of the present invention comprises: a first step for reacting an alkali metal hydroxide with 2,4-di-tertiary-butylphenol using 4-methyltetrahydropyran a...
|
|
WO/2023/189498A1 |
The purpose of the present invention is to provide a method for producing a 4,4'-dihydroxybiphenyl-3,3'-dicarboxylic acid at high yield. Disclosed is a method for producing a 4,4'-dihydroxybiphenyl-3,3'-dicarboxylic acid represented by f...
|
|
WO/2023/189961A1 |
This resist composition contains a resin component (A1) having: a constitutional unit (a01) derived from a compound represented by general formula (a0-1); and a constitutional unit (a02) including a lactone-containing cyclic group or the...
|
|
WO/2023/189499A1 |
The purpose of the present invention is to provide a production method by which 4,4'-dihydroxybiphenyl-3,3'-dicarboxylic acid can be obtained with a high yield. The present invention discloses a method for producing 4,4'-dihydroxybipheny...
|
|
WO/2023/176917A1 |
The purpose of the present invention is to provide an MOF that is capable of quickly adsorbing a target substance in accordance with a change in relative pressure and that exhibits an adsorption amount larger than or equal to a prescribe...
|
|
WO/2023/146513A1 |
Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating diseases. Specific diseases include those that are mediated by YAP/TAZ or those that are modulated by the interaction be...
|
|
WO/2023/147354A1 |
A method is provided for synthesizing multi-ring disalicylate linkers. The method can allow for synthesis of disalicylate linkers while using a reduced or minimized amount of solvent (such as down to potentially having no separate solven...
|
|
WO/2023/119507A1 |
[Problem] To increase the number of catechol sites for modification in a metal-organic framework. [Solution] This catechol-modified metal-organic framework comprises: a metal organic framework that contains a central metal and an organic...
|
|
WO/2023/119508A1 |
[Problem] To increase metal sites that modify a metal organic framework to increase the adsorption amount of a gas. [Solution] Provided is a metal-modified metal organic framework which comprises a metal organic framework containing a ce...
|
|
WO/2023/118454A1 |
Metal-organic framework material (MOF), comprising at least one metal center and at least one organic compound selected among the compounds according to formula (I): (I) - wherein n is from 1 to 2, - R is –(CH2-CH2-O)m-CH3 with m from ...
|
|
WO/2023/115116A1 |
The present invention relates to polynucleotides for the generation of genetically modified plants, algae or plastids thereof that are capable of producing cannabinoids. In an aspect, the present invention also relates to methods of prod...
|
|
WO/2023/122276A1 |
Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor positive allosteric modulators (PAMS), compositions comprising the compounds, and methods of using the compounds and compositions comprising the c...
|
|
WO/2023/109855A1 |
The present invention relates to a pharmaceutical cocrystal of curcumin, a preparation method therefor, and the use thereof as a drug or in a pharmaceutical preparation. The pharmaceutical cocrystal of curcumin has a good solubility, a g...
|
|
WO/2023/106242A1 |
Provided is a method for producing an aromatic hydroxycarboxylic acid crystal having high purity. The present invention pertains to a production method for an aromatic hydroxycarboxylic acid crystal, the method comprising a step for de...
|
|
WO/2023/094418A1 |
The present application relates to a metal-free photocatalytic method and system for converting polystyrene into benzoic acid, using a metal free catalytic system. In particular, the method and system described herein allow to generate b...
|
|
WO/2023/088285A1 |
A small molecule inhibitor targeting EB virus antigen protein, and/or a pharmaceutical composition comprising same, capable of being used for treating diseases caused by EB virus infection, such as, but not limited to, cancer, infectious...
|
|
WO/2023/091674A1 |
Described herein are compounds which are inhibitors of oncogenic and wild-type SHP2 and methods of treatment using SHP2 inhibitors.
|
|
WO/2023/076668A1 |
The invention provides a method of preventing or treating cancer in a subject by administering to the subject a therapeutically effective amount of a GPR84 antagonist. Also provided is a method of preventing recurrence of cancer in a sub...
|
|
WO/2022/115971A9 |
Disclosed are methods for separating, recovering, and purifying CBGA, CBDVA, THCVA, CBCVA, and CBCA from dewatered and desolventized crude complex extracts or mixtures of metabolites, cannabinoids, and cannabis phytochemicals. The method...
|
|
WO/2023/027168A1 |
According to the present method, salicylic acid is produced with high productivity by causing a 2-halogenated benzoic acid to react at 155-300°C in an aqueous solvent in the presence of a copper source and a ligand. Preferably, a refine...
|
|
WO/2023/018955A1 |
Solid forms including 7-[[(1S)-1-[4-[(1S)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin
-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4H-pyrimido[4,5-d][1
,3]oxazin-2-one and a dihydroxybenzoic acid selected from 2,5-dihydroxybenzoic acid, 2,4-dihy...
|
|
WO/2023/275864A1 |
The present disclosure generally relates to processes for the preparation of aqueous compositions comprising a cannabinoid acid or a salt thereof.
|
